This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mortgage Rates Fall to a 12-Month Low
by Zacks Equity Research
Mortgage Rates Fall to a 12-Month Low.
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
by Zacks Equity Research
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
by Zacks Equity Research
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
by Zacks Equity Research
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
Why Legend Biotech (LEGN) Stock Might be a Great Pick
by Kaibalya Pravo Dey
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Company News for Mar 12, 2024
by Zacks Equity Research
Companies in The News Are: LEGN, BA, ALK, FTRE, AVGO.
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
by Zacks Equity Research
Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
FDA Demands "Boxed Warning" to CAR T-Cell Therapy Labels
by Ekta Bagri
The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
by Ekta Bagri
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Will Top-Line Decline Hurt Keysight's (KEYS) Q4 Earnings?
by Zacks Equity Research
Keysight (KEYS) is expected to report a top line contraction year over year, owing to weakness in some consumer electronic markets stemming from inventory adjustments and macroeconomic headwinds.
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
by Zacks Equity Research
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
Will Revenue Growth Boost Keysight's (KEYS) Q3 Earnings?
by Zacks Equity Research
Keysight (KEYS) is expected to report higher revenues year over year in the third quarter of fiscal 2023, backed by a strong emphasis on innovation and rising demand for its electronic design and test solutions.
Why Earnings Season Could Be Great for Legend Biotech (LEGN)
by Zacks Equity Research
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
by Ekta Bagri
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Top 5 Stocks Set to Beat on Earnings Next Week
by Nalak Das
We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.
Will Top-line Expansion Boost Akamai (AKAM) Q2 Earnings?
by Zacks Equity Research
Akamai (AKAM) is expected to report higher revenues year over year in the second quarter of 2023, driven by positive demand trends in the compute and security verticals.
Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use
by Zacks Equity Research
Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.